Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma

Jeanne Palmer, T. Goggins, G. Broadwater, N. Chao, M. Horwitz, A. Beaven, K. Sullivan, R. E. Coleman, D. Rizzieri

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retrospectively analyzed patients who received auto-SCT for treatment of relapsed or refractory non-Hodgkins lymphoma or Hodgkins disease between the years of 1996 and 2007. Patients who had either a PET scan following salvage chemotherapy within 14 weeks of transplantation (pre-PET), and/or a PET scan 6-14 weeks following transplantation (post-PET) were included. A total of 90 patients were identified for analysis. The median follow-up time is 3.3 years, with a range of 0.13-12.0 years. The median PFS was 4.6 years, and median OS was 5.1 years. At the time of this analysis, 34 patients (37%) experienced disease relapse, and 25 (27%) of the patients died from disease progression. In multivariate Cox proportional hazards analysis, post-PET did not predict for outcome, pre-PET positivity predicted for decrease in PFS. In conclusion, post-PET scan did not predict for PFS or OS in multivariate analysis. Positive pre-PET scan did predict for PFS as seen in previous studies, and may help identify patients who would benefit from innovative post transplant therapies.

Original languageEnglish (US)
Pages (from-to)847-851
Number of pages5
JournalBone Marrow Transplantation
Volume46
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Hodgkin Disease
Positron-Emission Tomography
Non-Hodgkin's Lymphoma
Transplants
Transplantation
Disease Progression
Lymphoma
Multivariate Analysis
Tomography
Recurrence
Drug Therapy
Therapeutics

Keywords

  • autologous
  • FDG-PET
  • HSCT
  • lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. / Palmer, Jeanne; Goggins, T.; Broadwater, G.; Chao, N.; Horwitz, M.; Beaven, A.; Sullivan, K.; Coleman, R. E.; Rizzieri, D.

In: Bone Marrow Transplantation, Vol. 46, No. 6, 01.06.2011, p. 847-851.

Research output: Contribution to journalArticle

Palmer, Jeanne ; Goggins, T. ; Broadwater, G. ; Chao, N. ; Horwitz, M. ; Beaven, A. ; Sullivan, K. ; Coleman, R. E. ; Rizzieri, D. / Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 6. pp. 847-851.
@article{c9e18a4acc854d6d972669d7395bdab2,
title = "Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma",
abstract = "Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retrospectively analyzed patients who received auto-SCT for treatment of relapsed or refractory non-Hodgkins lymphoma or Hodgkins disease between the years of 1996 and 2007. Patients who had either a PET scan following salvage chemotherapy within 14 weeks of transplantation (pre-PET), and/or a PET scan 6-14 weeks following transplantation (post-PET) were included. A total of 90 patients were identified for analysis. The median follow-up time is 3.3 years, with a range of 0.13-12.0 years. The median PFS was 4.6 years, and median OS was 5.1 years. At the time of this analysis, 34 patients (37{\%}) experienced disease relapse, and 25 (27{\%}) of the patients died from disease progression. In multivariate Cox proportional hazards analysis, post-PET did not predict for outcome, pre-PET positivity predicted for decrease in PFS. In conclusion, post-PET scan did not predict for PFS or OS in multivariate analysis. Positive pre-PET scan did predict for PFS as seen in previous studies, and may help identify patients who would benefit from innovative post transplant therapies.",
keywords = "autologous, FDG-PET, HSCT, lymphoma",
author = "Jeanne Palmer and T. Goggins and G. Broadwater and N. Chao and M. Horwitz and A. Beaven and K. Sullivan and Coleman, {R. E.} and D. Rizzieri",
year = "2011",
month = "6",
day = "1",
doi = "10.1038/bmt.2010.203",
language = "English (US)",
volume = "46",
pages = "847--851",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma

AU - Palmer, Jeanne

AU - Goggins, T.

AU - Broadwater, G.

AU - Chao, N.

AU - Horwitz, M.

AU - Beaven, A.

AU - Sullivan, K.

AU - Coleman, R. E.

AU - Rizzieri, D.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retrospectively analyzed patients who received auto-SCT for treatment of relapsed or refractory non-Hodgkins lymphoma or Hodgkins disease between the years of 1996 and 2007. Patients who had either a PET scan following salvage chemotherapy within 14 weeks of transplantation (pre-PET), and/or a PET scan 6-14 weeks following transplantation (post-PET) were included. A total of 90 patients were identified for analysis. The median follow-up time is 3.3 years, with a range of 0.13-12.0 years. The median PFS was 4.6 years, and median OS was 5.1 years. At the time of this analysis, 34 patients (37%) experienced disease relapse, and 25 (27%) of the patients died from disease progression. In multivariate Cox proportional hazards analysis, post-PET did not predict for outcome, pre-PET positivity predicted for decrease in PFS. In conclusion, post-PET scan did not predict for PFS or OS in multivariate analysis. Positive pre-PET scan did predict for PFS as seen in previous studies, and may help identify patients who would benefit from innovative post transplant therapies.

AB - Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retrospectively analyzed patients who received auto-SCT for treatment of relapsed or refractory non-Hodgkins lymphoma or Hodgkins disease between the years of 1996 and 2007. Patients who had either a PET scan following salvage chemotherapy within 14 weeks of transplantation (pre-PET), and/or a PET scan 6-14 weeks following transplantation (post-PET) were included. A total of 90 patients were identified for analysis. The median follow-up time is 3.3 years, with a range of 0.13-12.0 years. The median PFS was 4.6 years, and median OS was 5.1 years. At the time of this analysis, 34 patients (37%) experienced disease relapse, and 25 (27%) of the patients died from disease progression. In multivariate Cox proportional hazards analysis, post-PET did not predict for outcome, pre-PET positivity predicted for decrease in PFS. In conclusion, post-PET scan did not predict for PFS or OS in multivariate analysis. Positive pre-PET scan did predict for PFS as seen in previous studies, and may help identify patients who would benefit from innovative post transplant therapies.

KW - autologous

KW - FDG-PET

KW - HSCT

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=79958145027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958145027&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.203

DO - 10.1038/bmt.2010.203

M3 - Article

C2 - 20856212

AN - SCOPUS:79958145027

VL - 46

SP - 847

EP - 851

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -